One Blue-Chip Stock Is Up 11% While the S&P 500 Struggles

The S&P 500 has had a rough 2026. Johnson & Johnson has not.

Benzinga • 14 hours ago

Congressman A Big Fan Of Dividend Reinvestments: Here's His Core Blue Chip Stocks

Tracking the trading activity of members of Congress can reveal unusual timed purchases based on congressional committees and world events. For one member of Congress, tracking reveals a preference to invest in the same stocks over and over again using the dividend reinvestment method.

Benzinga • 12 hours ago

How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?

ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.

Zacks Investment Research • 15 hours ago

Why Is Johnson & Johnson (JNJ) Down 3.5% Since Last Earnings Report?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • May 14, 2026

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives Among patients treated with BCG, three- quarters describe managing the treatment- related physical symptoms as humiliating Patients and urologists point to the importance of advancing treatments that may better reflect patient preferences and quality-of-life considerations WASHINGTON, May 14, 2026 /PRNewswire/ -- A new global survey of patient and urologist perception and experience—conducted in collaboration with leading bladder cancer professional and patient organizations—reveals the physical, mental, and emotional toll associated with standard-of-care therapies for bladder cancer, including surgery to remove the bladder and Bacillus Calmette-Guérin (BCG) treatment. Released ahead of the American Urological Association (AUA) Annual Meeting, the findings highlight patient experiences that may not always be fully surfaced and discussed during care, pointing to opportunities to strengthen support and continue advancing innovative treatment approaches.

PRNewsWire • May 14, 2026

Russell 1000 Dividend ETF Hits $125 as Johnson & Johnson Leads The Safety Test

The SPDR Russell 1000 Yield Focus ETF (NYSEARCA:ONEY) harvests income from large-cap American stocks by screening the Russell 1000 for companies combining high yield with quality and low financial risk.

24/7 Wall Street • May 13, 2026

The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio

S&P Global rates only two U.S. public companies AAA, one notch above the federal government itself.

24/7 Wall Street • May 13, 2026

Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 12, 2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter.

Business Wire • May 12, 2026

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

Zacks Investment Research • May 12, 2026